---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-130675"
form_type: "8-K"
ticker: "MRK"
cik: "0000310158"
company_name: "Merck & Co., Inc."
filed_at: "2021-10-28T23:59:59+00:00"
generated_at: "2026-06-28T17:00:55.211907+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Merck Q3 sales $13.2B (+20% YoY); raises FY2021 guidance; to acquire Acceleron for $11.5B

## Summary
- Q3 GAAP EPS $1.80, Non-GAAP EPS $1.75; sales $13.2B (+20% YoY, +19% ex-FX).
- Keytruda sales $4.5B (+22%); Gardasil $2.0B (+68%); Animal Health $1.4B (+16%).
- Raises FY2021 revenue guidance to $47.4B–$47.9B; Non-GAAP EPS to $5.65–$5.70.
- Agreement to acquire Acceleron Pharma for $180/share (~$11.5B); expected close Q4 2021.
- Submitted EUA for molnupiravir (oral COVID-19 treatment) based on positive Phase 3 data.

## SEC filing metadata
- accession: 0001104659-21-130675
- form_type: 8-K
- ticker: MRK
- cik: 0000310158
- company_name: Merck & Co., Inc.
- filed_at: 2021-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/310158/000110465921130675/0001104659-21-130675-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/310158/000110465921130675/tm2131077d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-130675
- JSON: https://secwatch.observer/filing/0001104659-21-130675.json
- Plain text: https://secwatch.observer/filing/0001104659-21-130675.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.